Ligand ID: 20J


Drugbank ID:
DB01119
(Diazoxide)


Indication:
Used parentally to treat hypertensive emergencies. Also used to treat hypoglycemia secondary to insulinoma.

Get human targets for 20J in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND '20J'

Click here for results that match SARS-Cov-2 / COVID-19 structures only
Click here for results that match SARS-related structures only


1) User may click on the DrReposER ID (the second column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera through AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		1q2w 3C-LIKE PROTEASE
(SARSr-CoV)		4 / 8
SER B 144
ALA B 116
SER B 123
ARG A 298
1.59A20.16
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		1q2w 3C-LIKE PROTEASE
(SARSr-CoV)		4 / 7
SER B 144
ALA B 116
SER B 123
ARG A 298
1.57A20.16
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		1q2w 3C-LIKE PROTEASE
(SARSr-CoV)		4 / 7
TYR B 209
ARG B 217
ILE B 281
ALA B 211
1.14A20.16
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		1uj1 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 8
SER B 144
ALA B 116
SER B 123
TYR B 126
1.67A20.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		1uj1 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 7
TYR B 126
SER B 144
ALA B 116
SER B 123
1.67A20.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		1x7q HLA, A-11
(Homo
sapiens)		4 / 7
TYR A   9
ASP A  74
SER A  11
ARG A 114
1.70A17.67
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		1x7q HLA, A-11
(Homo
sapiens)		4 / 8
ASP A  74
SER A  11
ARG A 114
TYR A   9
1.67A17.67
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		1z1j 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 7
SER B1144
ALA B1116
SER B1123
ARG A 298
1.49A20.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		1z1j 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 8
SER B1144
ALA B1116
SER B1123
ARG A 298
1.51A20.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		2a5k 3C-LIKE PEPTIDASE
(SARSr-CoV)		4 / 8
SER B 144
ALA B 116
SER B 123
ARG A 298
1.65A20.50
AZP  B 307 (-3.6A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		2a5k 3C-LIKE PEPTIDASE
(SARSr-CoV)		4 / 7
SER B 144
ALA B 116
SER B 123
ARG A 298
1.63A20.50
AZP  B 307 (-3.6A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		2ahm REPLICASE
POLYPROTEIN 1AB,
HEAVY CHAIN
(SARSr-CoV)		4 / 8
ARG G  62
ASP G  57
SER G  16
SER G  52
1.72A16.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		2cjr NUCLEOCAPSID PROTEIN
(SARS-COV
TW1)		4 / 7
TYR D 269
PHE D 275
ALA D 255
ARG D 263
1.34A14.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		2cjr NUCLEOCAPSID PROTEIN
(SARS-COV
TW1)		4 / 8
PHE D 275
ALA D 255
ARG D 263
TYR D 269
1.34A14.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		2d2d 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 7
TYR A 209
ARG A 217
ILE A 281
ALA A 211
1.11A20.45
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		2fe8 REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		4 / 8
ARG C  83
ASP A  77
SER A  79
SER B  79
1.31A21.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		2ghw ANTI-SCFV ANTIBODY,
80R
(Homo
sapiens)		4 / 8
PHE B  68
ARG B  87
ALA B  61
ARG B  38
1.60A19.92
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		2ghw SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 7
TYR C 494
VAL C 496
ILE C 397
ARG C 395
ILE C 405
1.61A16.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		2op9 REPLICASE
POLYPROTEIN 1AB
(PP1AB, ORF1AB)
3C-LIKE PROTEINASE
(3CL-PRO, 3CLP)
(SARSr-CoV)		4 / 7
TYR B 209
ARG B 217
ILE B 281
ALA B 211
1.15A19.68
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		2pwx 3C-LIKE PROTEINASE
(SARS-COV
BJ01)		4 / 7
TYR A 209
ARG A 217
ILE A 281
ALA A 211
1.19A20.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		2q6g REPLICASE
POLYPROTEIN 1AB
(SARS-COV
BJ01)		4 / 7
TYR A 209
ARG A 217
ILE A 281
ALA A 211
0.95A20.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		4 / 7
PHE E 240
ALA E 283
SER E 261
ARG E 257
1.71A22.07
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		4 / 8
PHE E 240
ALA E 283
SER E 261
ARG E 257
1.72A22.07
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		2vj1 MAIN PROTEINASE
(SARSr-CoV)		4 / 7
TYR A 209
ARG A 217
ILE A 281
ALA A 211
1.13A20.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		2wct NSP3
(SARSr-CoV)		4 / 7
ASP A 424
SER A 516
SER A 626
ARG A 628
1.77A21.64
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		2wct NSP3
(SARSr-CoV)		4 / 7
VAL C 611
ARG C 554
ILE C 556
ALA C 555
1.09A21.64
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		2xyq PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		4 / 7
TYR A 181
VAL A 169
ILE A 167
ILE A 157
1.19A20.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		2xyr PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		4 / 7
TYR A 181
VAL A 169
ILE A 167
ILE A 157
1.18A20.43
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		3atw 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 8
SER A 144
ALA A 116
SER A 123
ARG B 298
1.27A20.25
HSV  C   5 (-3.6A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		3atw 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 7
SER A 144
ALA A 116
SER A 123
ARG B 298
1.27A20.25
HSV  C   5 (-3.6A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		3bgf F26G19 FAB
(Mus
musculus)		4 / 8
ARG H 100
SER L  34
ALA L  50
TYR L  49
1.52A19.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		3bgf F26G19 FAB
(Mus
musculus)		4 / 8
SER C  72
ALA C  51
SER C  52
TYR C  71
1.45A19.67
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		3bgf F26G19 FAB
(Mus
musculus)		4 / 7
TYR C  71
SER C  72
ALA C  51
SER C  52
1.45A19.67
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		3d0h ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		4 / 8
PHE B 356
ASP B 350
ALA B 386
TYR B 385
1.68A20.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		3d0h ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		4 / 7
TYR B 385
PHE B 356
ASP B 350
ALA B 386
1.69A20.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		3ea7 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 7
TYR A 209
ARG A 217
ILE A 281
ALA A 211
1.09A20.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		3ebn REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		4 / 7
VAL C 212
ILE A 259
ARG A 222
ALA A 267
1.21A12.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		3f9f 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 8
ARG A 298
SER B 139
ALA B 116
SER B 144
1.58A20.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		3f9g 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 7
TYR B 126
SER B 144
ALA B 116
SER B 123
1.72A19.45
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		3i6l HLA, A-24
NUCLEOPROTEIN
PEPTIDE
(Homo
sapiens;
SARSr-CoV)		4 / 7
PHE F   2
SER D  71
ALA D  24
SER D   9
1.75A1.61
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		3m3v 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 8
SER A 144
ALA A 116
SER A 123
TYR A 126
1.68A20.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		3m3v 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 7
TYR A 126
SER A 144
ALA A 116
SER A 123
1.68A20.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		3r24 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		4 / 7
TYR A 181
VAL A 169
ILE A 167
ILE A 157
1.17A19.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		3sci ACE2
(Homo
sapiens)		4 / 7
TYR B 385
PHE B 356
ASP B 350
ALA B 386
1.71A21.27
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		3sci ACE2
(Homo
sapiens)		4 / 8
PHE B 356
ASP B 350
ALA B 386
TYR B 385
1.70A21.27
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		3scl ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		4 / 7
TYR A 385
PHE A 356
ASP A 350
ALA A 386
1.67A21.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		3scl ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		4 / 8
PHE A 356
ASP A 350
ALA A 386
TYR A 385
1.66A21.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		3snd 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 7
TYR B 209
ARG B 217
ILE B 281
ALA B 211
1.07A20.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		3to2 MD3-C9 PEPTIDE
DERIVED FROM
MEMBRANE
GLYCOPROTEIN
MHC CLASS I ANTIGEN
(Homo
sapiens;
SARS-COV
TJF)		4 / 7
TYR A 118
VAL C   9
ILE A 124
ALA A 136
1.15A17.68
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		5b6o 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 7
SER B 144
ALA B 116
SER B 123
ARG A 298
1.69A19.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		5b6o 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 8
SER B 144
ALA B 116
SER B 123
ARG A 298
1.72A19.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		5c8s GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		4 / 7
TYR D 420
PHE D 401
SER D 418
SER D 407
1.54A22.01
G3A  D 606 (-4.3A)
G3A  D 606 (-3.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		5c8s GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		4 / 8
PHE D 401
SER D 418
SER D 407
TYR D 420
1.50A22.01
G3A  D 606 (-3.8A)
None
None
G3A  D 606 (-4.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		5c8s GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		4 / 7
VAL D 182
ILE D 242
ARG D  76
ALA D 281
1.08A22.01
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		5c8s GUANINE-N7
METHYLTRANSFERASE
NSP10
(SARSr-CoV)		4 / 7
TYR C  27
VAL D  66
ILE D 201
ALA C  20
1.17A13.61
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		5c8t GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		4 / 7
VAL D 182
ILE D 242
ARG D  76
ALA D 281
1.03A21.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		5c8u GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		4 / 7
PHE D 436
ASP D 432
ALA D 430
ARG D 400
1.64A21.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		5nfy POLYPROTEIN 1AB
(SARS-COV
Frankfurt
1)		4 / 7
TYR C 420
PHE C 401
SER C 418
SER C 407
1.53A21.91
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		5nfy POLYPROTEIN 1AB
(SARS-COV
Frankfurt
1)		4 / 8
PHE C 401
SER C 418
SER C 407
TYR C 420
1.50A21.91
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
TYR A 209
VAL A 204
ILE A 281
ALA A 211
1.55A14.78
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
TYR A 209
ARG A 217
ILE A 281
ALA A 211
1.26A14.78
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
TYR A 209
VAL A 204
ILE A 281
ALA A 211
1.55A14.78
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
TYR A 209
ARG A 217
ILE A 281
ALA A 211
1.24A14.78
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		5tl7 REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		4 / 7
TYR D  84
PHE D  80
SER D  86
ALA D 150
1.78A21.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		5x4r S PROTEIN
(MERS-CoV)		4 / 8
ARG A 301
SER A  25
ALA A  29
SER A  28
1.66A21.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		5x4s SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 7
PHE A 262
ASP A 277
SER A 279
SER A  64
1.77A19.49
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		4 / 7
PHE A 193
ASP A 191
SER C 500
ARG C 342
1.20A18.40
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		4 / 8
PHE A 193
ASP A 191
SER C 500
ARG C 342
1.16A18.40
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		5x5c S PROTEIN
(MERS-CoV)		4 / 8
ARG B 505
SER C 435
ALA C 431
SER C 429
1.49A17.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		5xlr SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 8
ARG A  38
ASP A 277
SER A 279
ALA A 284
1.63A18.86
ARG  A  38 ( 0.6A)
ASP  A 277 ( 0.6A)
SER  A 279 ( 0.0A)
ALA  A 284 ( 0.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		5xlr SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 7
TYR C  63
PHE C  62
SER C  36
ARG C  38
1.72A18.86
TYR  C  63 ( 1.3A)
PHE  C  62 ( 1.3A)
SER  C  36 ( 0.0A)
ARG  C  38 ( 0.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		5xlr SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 7
VAL B 628
ILE B 656
ILE B 652
ALA B 658
0.96A18.86
VAL  B 628 ( 0.6A)
ILE  B 656 ( 0.7A)
ILE  B 652 ( 0.7A)
ALA  B 658 ( 0.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6acc SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 7
VAL B 628
ILE B 656
ILE B 652
ALA B 658
0.80A18.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 7
PHE C 558
ASP C 557
SER B 949
SER B 956
1.41A18.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 8
PHE C 558
ASP C 557
SER B 949
SER B 956
1.40A18.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6crz SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 7
TYR A 494
VAL A 496
ILE A 397
ILE A 405
1.18A18.68
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6cs1 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 7
TYR B 383
PHE B 416
SER B 500
SER B 380
1.61A18.68
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6cs1 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 8
PHE A 193
ARG C 342
SER C 380
TYR C 383
1.54A18.68
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6cs2 ACE2
(Homo
sapiens)		4 / 8
PHE D 356
ASP D 350
ALA D 386
TYR D 385
1.68A20.71
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6cs2 ACE2
(Homo
sapiens)		4 / 7
TYR D 385
PHE D 356
ASP D 350
ALA D 386
1.72A20.71
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6lze VIRAL PROTEASE
(SARS-CoV-2)		4 / 7
TYR A 209
VAL A 204
ILE A 281
ALA A 211
1.55A21.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6lze VIRAL PROTEASE
(SARS-CoV-2)		4 / 7
TYR A 209
VAL A 204
ILE A 281
ALA A 211
1.54A21.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6lzg SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
TYR B 451
VAL B 510
ARG B 403
ILE B 418
1.23A20.51
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6m03 MAIN PROTEASE
(SARS-CoV-2)		4 / 7
TYR A 209
ARG A 217
ILE A 281
ALA A 211
1.08A21.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6m0j SPIKE RECEPTOR
BINDING DOMAIN
(SARS-CoV-2)		4 / 7
TYR E 451
PHE E 347
SER E 438
ARG E 509
1.53A20.51
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6m0j SPIKE RECEPTOR
BINDING DOMAIN
(SARS-CoV-2)		4 / 8
PHE E 347
SER E 438
ARG E 509
TYR E 451
1.56A20.51
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		4 / 7
TYR A 209
VAL A 204
ILE A 281
ALA A 211
1.55A21.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		4 / 7
TYR A 209
VAL A 204
ILE A 281
ALA A 211
1.55A21.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6m17 RECEPTOR BINDING
DOMAIN
(SARS-CoV-2)		4 / 7
TYR E 451
PHE E 497
ASP E 442
SER E 438
1.56A19.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6m17 SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		4 / 7
PHE A 550
SER A 491
ALA A 590
SER A 594
1.49A21.84
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6m17 SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		4 / 8
PHE A 550
SER A 491
ALA A 590
SER A 594
1.51A21.84
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6m17 RECEPTOR BINDING
DOMAIN
(SARS-CoV-2)		4 / 8
PHE F 497
ASP F 442
SER F 438
TYR F 451
1.56A19.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6m18 ACE2
(Homo
sapiens)		4 / 8
PHE D 356
ASP D 350
ALA D 386
TYR D 385
1.71A20.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6m18 ACE2
(Homo
sapiens)		4 / 7
TYR B 385
PHE B 356
ASP B 350
ALA B 386
1.72A20.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6m1d ACE2
(Homo
sapiens)		4 / 7
HIS D 373
ILE D 307
ARG D 306
ALA D 311
1.22A20.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
TYR B 209
VAL B 204
ILE B 281
ALA B 211
1.58A21.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
TYR D 209
VAL D 204
ILE D 281
ALA D 211
1.44A21.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
TYR C 209
VAL C 204
ILE C 281
ALA C 211
1.55A21.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
TYR C 209
VAL C 204
ILE C 281
ALA C 211
1.55A21.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
TYR A 209
VAL A 204
ILE A 281
ALA A 211
1.57A21.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
TYR D 209
VAL D 204
ILE D 281
ALA D 211
1.45A21.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6m2q 3CL PROTEASE
(SARS-CoV-2)		4 / 7
TYR A 209
VAL A 204
ILE A 281
ALA A 211
1.54A21.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6m2q 3CL PROTEASE
(SARS-CoV-2)		4 / 7
TYR A 209
VAL A 204
ILE A 281
ALA A 211
1.54A21.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6m3m NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
ARG A 108
SER C  52
ALA C  56
ARG C 108
1.60A14.16
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6m71 NSP7
NSP8
(SARS-CoV-2)		4 / 7
VAL C  53
ILE D 106
ILE D 107
ALA D 110
1.68A12.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6m71 NSP12
(SARS-CoV-2)		4 / 8
ARG A 553
ASP A 452
ALA A 558
SER A 681
1.77A20.75
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6m71 NSP12
(SARS-CoV-2)		4 / 7
TYR A 237
VAL A 182
ILE A 244
ARG A 132
1.46A20.75
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6m71 NSP12
(SARS-CoV-2)		4 / 7
TYR A 237
VAL A 182
ILE A 244
ARG A 132
1.44A20.75
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6nb8 S230 ANTIGEN-BINDING
(FAB) FRAGMENT,
HEAVY CHAIN
(Homo
sapiens)		4 / 8
PHE H  68
ARG H  87
ALA H  61
ARG H  38
1.55A18.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
PHE A 347
SER A 438
ARG A 509
TYR A 451
1.64A19.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
VAL A1065
ILE A 720
ILE A 923
ALA A 924
1.23A19.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
TYR A 451
PHE A 347
SER A 438
ARG A 509
1.61A19.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6vw1 ACE2
(Homo
sapiens)		4 / 7
TYR B 385
PHE B 356
ASP B 350
ALA B 386
1.72A20.16
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6vw1 ACE2
(Homo
sapiens)		4 / 8
PHE B 356
ASP B 350
ALA B 386
TYR B 385
1.70A20.16
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6vxs NSP3
(SARS-CoV-2)		4 / 7
TYR A 152
VAL A  30
ILE A  23
ALA A 124
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6vxs NSP3
(SARS-CoV-2)		4 / 7
TYR B 152
VAL B  30
ILE B  23
ALA B 124
1.45A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6vxs NSP3
(SARS-CoV-2)		4 / 7
TYR B 152
VAL B  30
ILE B  23
ALA B 124
1.46A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6vxs NSP3
(SARS-CoV-2)		4 / 7
TYR A 152
VAL A  30
ILE A  23
ALA A 124
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
VAL A 597
ILE A 312
ILE A 664
ALA A 672
1.25A19.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
PHE A 194
ALA A  93
SER A  94
TYR A  91
1.67A19.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
TYR A  91
PHE A 194
ALA A  93
SER A  94
1.65A19.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
PHE C 823
ASP C 820
SER C 813
ALA C 871
1.56A19.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
PHE C 823
ASP C 820
SER C 813
ALA C 871
1.53A19.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
VAL C 597
ILE C 312
ILE C 664
ALA C 672
1.24A19.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 7
TYR C 453
PHE C 497
SER C 349
ARG C 403
1.29A15.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 8
PHE C 347
ARG C 346
ASP C 442
SER C 438
1.62A15.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 7
TYR C 508
VAL C 510
ARG C 408
ILE C 418
1.35A15.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 7
TYR C 508
VAL C 510
ILE C 410
ILE C 418
1.34A15.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 8
PHE C 497
SER C 349
ARG C 403
TYR C 453
1.30A15.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 7
TYR C 451
PHE C 497
ASP C 442
SER C 438
1.76A15.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 7
TYR C 508
VAL C 510
ILE C 410
ILE C 418
1.34A15.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 7
TYR C 508
VAL C 510
ARG C 408
ILE C 418
1.34A15.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 8
PHE C 497
ASP C 442
SER C 438
TYR C 451
1.76A15.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w4b NSP9
(SARS-CoV-2)		4 / 8
ASP A  27
SER A  14
ALA A  29
SER A  47
1.56A13.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w4b NSP9
(SARS-CoV-2)		4 / 7
ASP A  27
SER A  14
ALA A  29
SER A  47
1.53A13.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
TYR A6845
ILE A6925
ILE A6967
ALA A6966
1.78A15.88
SAM  A7104 (-4.6A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w61 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 7
TYR A6845
VAL B4295
ILE A6838
ALA A6843
1.44A
SAM  A7104 (-4.6A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w61 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 7
TYR A6845
VAL B4295
ILE A6838
ALA A6843
1.44A
SAM  A7104 (-4.6A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
TYR A6845
ILE A6925
ILE A6967
ALA A6966
1.76A15.88
SAM  A7104 (-4.6A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
TYR A 209
VAL A 204
ILE A 281
ALA A 211
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
TYR A 209
VAL A 204
ILE A 281
ALA A 211
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
TYR A 209
ARG A 217
ILE A 281
ALA A 211
1.15A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w6y NSP3
(SARS-CoV-2)		4 / 7
TYR B 152
VAL B  30
ILE B  23
ALA B 124
1.46A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w6y NSP3
(SARS-CoV-2)		4 / 7
TYR B 152
VAL B  30
ILE B  23
ALA B 124
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w6y NSP3
(SARS-CoV-2)		4 / 7
HIS A  94
VAL A  35
ILE A  23
ALA A  50
1.77A18.22
None
None
AMP  A 201 ( 4.0A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w6y NSP3
(SARS-CoV-2)		4 / 7
HIS A  94
VAL A  35
ILE A  23
ALA A  50
1.77A18.22
None
None
AMP  A 201 ( 4.0A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w6y NSP3
(SARS-CoV-2)		4 / 7
HIS B  94
VAL B  35
ILE B  23
ALA B  50
1.76A18.22
None
None
None
MES  B 201 ( 3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w6y NSP3
(SARS-CoV-2)		4 / 7
TYR A 152
VAL A  30
ILE A  23
ALA A 124
1.47A
None
None
AMP  A 201 ( 4.0A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w6y NSP3
(SARS-CoV-2)		4 / 7
TYR A 152
VAL A  30
ILE A  23
ALA A 124
1.46A
None
None
AMP  A 201 ( 4.0A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w6y NSP3
(SARS-CoV-2)		4 / 7
HIS B  94
VAL B  35
ILE B  23
ALA B  50
1.77A18.22
None
None
None
MES  B 201 ( 3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w75 NSP10
NSP16
(SARS-CoV-2)		4 / 7
TYR C6845
VAL D4295
ILE C6838
ALA C6843
1.42A15.83
SAM  C7105 ( 4.5A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w75 NSP10
NSP16
(SARS-CoV-2)		4 / 7
TYR C6845
VAL D4295
ILE C6838
ALA C6843
1.43A15.83
SAM  C7105 ( 4.5A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w75 NSP16
(SARS-CoV-2)		4 / 7
TYR C6861
ARG C7077
ILE C7079
ALA C6858
1.53A15.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w75 NSP10
NSP16
(SARS-CoV-2)		4 / 7
TYR A6845
VAL B4295
ILE A6838
ALA A6843
1.45A15.83
SAM  A7102 ( 4.5A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w75 NSP16
(SARS-CoV-2)		4 / 7
TYR C6845
ILE C6925
ILE C6967
ALA C6966
1.71A15.83
SAM  C7105 ( 4.5A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w75 NSP16
(SARS-CoV-2)		4 / 7
TYR C6861
ARG C7077
ILE C7079
ALA C6858
1.54A15.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w75 NSP16
(SARS-CoV-2)		4 / 7
TYR A6845
ILE A6925
ILE A6967
ALA A6966
1.69A15.83
SAM  A7102 ( 4.5A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w75 NSP16
(SARS-CoV-2)		4 / 7
TYR C6845
ILE C6925
ILE C6967
ALA C6966
1.68A15.83
SAM  C7105 ( 4.5A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w75 NSP10
NSP16
(SARS-CoV-2)		4 / 7
TYR A6845
VAL B4295
ILE A6838
ALA A6843
1.45A15.83
SAM  A7102 ( 4.5A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w75 NSP16
(SARS-CoV-2)		4 / 7
TYR A6845
ILE A6925
ILE A6967
ALA A6966
1.72A15.83
SAM  A7102 ( 4.5A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 7
TYR C 273
HIS C 272
ILE C 285
ALA C 114
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 7
TYR C 273
HIS C 272
ILE C 285
ALA C 114
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 7
TYR A 273
HIS A 272
ILE A 285
ALA A 114
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
PHE B 304
ASP B 302
SER B 262
ALA B 116
1.72A21.43
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 7
TYR B 273
HIS B 272
ILE B 285
ALA B 114
1.53A
None
None
CL  B 502 (-4.9A)
CL  B 502 ( 3.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 7
TYR B 273
HIS B 272
ILE B 285
ALA B 114
1.51A
None
None
CL  B 502 (-4.9A)
CL  B 502 ( 3.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 7
TYR A 273
HIS A 272
ILE A 285
ALA A 114
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w9q 3C-LIKE PROTEINASE
PEPTIDE, NSP9 FUSION
(SARS-CoV-2)		4 / 7
ASP A  26
SER A  13
ALA A  28
SER A  46
1.58A14.29
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6w9q 3C-LIKE PROTEINASE
PEPTIDE, NSP9 FUSION
(SARS-CoV-2)		4 / 8
ASP A  26
SER A  13
ALA A  28
SER A  46
1.62A14.29
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wcf NSP3
(SARS-CoV-2)		4 / 7
TYR A 152
VAL A  30
ILE A  23
ALA A 124
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wcf NSP3
(SARS-CoV-2)		4 / 7
TYR A 152
VAL A  30
ILE A  23
ALA A 124
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wen NSP3
(SARS-CoV-2)		4 / 7
TYR A 152
VAL A  30
ILE A  23
ALA A 124
1.42A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wen NSP3
(SARS-CoV-2)		4 / 7
TYR A 152
VAL A  30
ILE A  23
ALA A 124
1.43A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wey NSP3
(SARS-CoV-2)		4 / 7
TYR A 356
VAL A 234
ILE A 227
ALA A 328
1.44A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wey NSP3
(SARS-CoV-2)		4 / 7
TYR A 356
VAL A 234
ILE A 227
ALA A 328
1.43A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wiq NSP8
(SARS-CoV-2)		4 / 7
VAL B 130
ILE B 120
ILE B 106
ALA B 150
1.45A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wiq NSP8
(SARS-CoV-2)		4 / 7
VAL B 130
ILE B 120
ILE B 106
ALA B 150
1.42A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 7
TYR C6845
VAL D4295
ILE C6838
ALA C6843
1.43A
SAH  C7102 (-4.6A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 7
TYR A6845
VAL B4295
ILE A6838
ALA A6843
1.43A
SAH  A7102 (-4.6A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
TYR A6845
ILE A6925
ILE A6967
ALA A6966
1.71A
SAH  A7102 (-4.6A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
TYR C6845
ILE C6925
ILE C6967
ALA C6966
1.69A
SAH  C7102 (-4.6A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
TYR C6861
ARG C7077
ILE C7079
ALA C6858
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
TYR C6861
ARG C7077
ILE C7079
ALA C6858
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
TYR A6845
ILE A6925
ILE A6967
ALA A6966
1.68A
SAH  A7102 (-4.6A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 7
TYR A6845
VAL B4295
ILE A6838
ALA A6843
1.43A
SAH  A7102 (-4.6A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 7
TYR C6845
VAL D4295
ILE C6838
ALA C6843
1.42A
SAH  C7102 (-4.6A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
TYR C6845
ILE C6925
ILE C6967
ALA C6966
1.67A
SAH  C7102 (-4.6A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 7
TYR A 109
ILE B 157
ARG B 149
ALA A 156
1.69A
MES  B 201 (-4.3A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 7
TYR A 109
ILE B 157
ARG B 149
ALA A 156
1.69A
MES  B 201 (-4.3A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wkq NSP16
(SARS-CoV-2)		4 / 7
TYR C6845
ILE C6925
ILE C6967
ALA C6966
1.69A
SFG  C7103 ( 4.5A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wkq NSP10
NSP16
(SARS-CoV-2)		4 / 7
TYR C6845
VAL D4295
ILE C6838
ALA C6843
1.42A
SFG  C7103 ( 4.5A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wkq NSP16
(SARS-CoV-2)		4 / 7
TYR C6861
ARG C7077
ILE C7079
ALA C6858
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wkq NSP10
NSP16
(SARS-CoV-2)		4 / 7
TYR A6845
VAL B4295
ILE A6838
ALA A6843
1.43A
SFG  A7103 ( 4.6A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wkq NSP16
(SARS-CoV-2)		4 / 7
TYR A6845
ILE A6925
ILE A6967
ALA A6966
1.71A
SFG  A7103 ( 4.6A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wkq NSP16
(SARS-CoV-2)		4 / 7
TYR A6845
ILE A6925
ILE A6967
ALA A6966
1.69A
SFG  A7103 ( 4.6A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wkq NSP10
NSP16
(SARS-CoV-2)		4 / 7
TYR C6845
VAL D4295
ILE C6838
ALA C6843
1.42A
SFG  C7103 ( 4.5A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wkq NSP10
NSP16
(SARS-CoV-2)		4 / 7
TYR A6845
VAL B4295
ILE A6838
ALA A6843
1.43A
SFG  A7103 ( 4.6A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wkq NSP16
(SARS-CoV-2)		4 / 7
TYR C6845
ILE C6925
ILE C6967
ALA C6966
1.71A
SFG  C7103 ( 4.5A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wkq NSP16
(SARS-CoV-2)		4 / 7
TYR C6861
ARG C7077
ILE C7079
ALA C6858
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
TYR B 231
VAL B 304
ILE B 236
ALA B 232
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
TYR A 231
VAL A 304
ILE A 236
ALA A 232
1.60A
SO4  A 410 (-3.3A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
TYR A 231
VAL A 304
ILE A 236
ALA A 232
1.58A
SO4  A 410 (-3.3A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
TYR B 231
VAL B 304
ILE B 236
ALA B 232
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
TYR A 209
VAL A 204
ILE A 281
ALA A 211
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
TYR A 209
VAL A 204
ILE A 281
ALA A 211
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
TYR B 152
VAL B  30
ILE B  23
ALA B 124
1.49A
None
None
APR  B 201 (-3.8A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
TYR C 152
VAL C  30
ILE C  23
ALA C 124
1.46A
None
None
APR  C 201 (-3.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
TYR B 152
VAL B  30
ILE B  23
ALA B 124
1.50A
None
None
APR  B 201 (-3.8A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
TYR A 152
VAL A  30
ILE A  23
ALA A 124
1.49A
None
None
APR  A 201 (-4.0A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
TYR C 152
VAL C  30
ILE C  23
ALA C 124
1.48A
None
None
APR  C 201 (-3.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
TYR A 152
VAL A  30
ILE A  23
ALA A 124
1.48A
None
None
APR  A 201 (-4.0A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
TYR D 152
VAL D  30
ILE D  23
ALA D 124
1.51A
None
None
APR  D 201 (-3.8A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
TYR D 152
VAL D  30
ILE D  23
ALA D 124
1.50A
None
None
APR  D 201 (-3.8A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wq3 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 7
TYR A6845
VAL B4295
ILE A6838
ALA A6843
1.43A
SAH  A7101 (-4.5A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
TYR A6845
ILE A6925
ILE A6967
ALA A6966
1.72A
SAH  A7101 (-4.5A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wq3 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 7
TYR A6845
VAL B4295
ILE A6838
ALA A6843
1.43A
SAH  A7101 (-4.5A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
TYR A6950
PHE A6954
SER A6927
SER A6896
1.78A21.04
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wqd NSP8
(SARS-CoV-2)		4 / 7
VAL B 130
ILE B 120
ILE B 106
ALA B 150
1.40A
None
None
None
EDO  B 302 (-3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wqd NSP8
(SARS-CoV-2)		4 / 7
VAL B 130
ILE B 120
ILE B 106
ALA B 150
1.38A
None
None
None
EDO  B 302 (-3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wqd NSP8
(SARS-CoV-2)		4 / 7
VAL D 130
ILE D 120
ILE D 106
ALA D 150
1.38A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wqd NSP8
(SARS-CoV-2)		4 / 7
VAL D 130
ILE D 120
ILE D 106
ALA D 150
1.41A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
TYR A 209
ARG A 217
ILE A 281
ALA A 211
1.29A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
TYR A 209
VAL A 204
ILE A 281
ALA A 211
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
TYR A 209
VAL A 204
ILE A 281
ALA A 211
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wrh PEPTIDASE C16
(SARS-CoV-2)		4 / 7
TYR A 273
HIS A 272
ILE A 285
ALA A 114
1.60A
GOL  A 508 (-4.9A)
PO4  A 502 (-3.7A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6wrh PEPTIDASE C16
(SARS-CoV-2)		4 / 7
TYR A 273
HIS A 272
ILE A 285
ALA A 114
1.57A
GOL  A 508 (-4.9A)
PO4  A 502 (-3.7A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6y2g REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
ARG A   4
SER B 144
ALA B 116
SER B 123
1.40A21.05
None
O6K  B 401 ( 3.9A)
None
GLY  A 401 ( 4.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
TYR A 209
ARG A 217
ILE A 281
ALA A 211
1.21A15.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
TYR A 209
ARG A 217
ILE A 281
ALA A 211
1.24A15.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
TYR A 209
VAL A 204
ILE A 281
ALA A 211
1.54A15.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
TYR A 209
VAL A 204
ILE A 281
ALA A 211
1.54A15.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		4 / 7
VAL D 130
ILE D 120
ILE D 106
ALA D 150
1.42A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		4 / 7
VAL D 130
ILE D 120
ILE D 106
ALA D 150
1.45A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		4 / 7
VAL B 130
ILE B 120
ILE B 106
ALA B 150
1.38A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		4 / 7
VAL B 130
ILE B 120
ILE B 106
ALA B 150
1.42A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6yi3 NUCLEOPROTEIN
(SARS-CoV-2)		4 / 7
TYR A  72
ILE A  90
ARG A  48
ILE A  91
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
TYR E 508
VAL E 510
ILE E 410
ILE E 418
1.39A
DMS  E 902 (-4.0A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
TYR A 508
VAL A 510
ILE A 410
ILE A 418
1.38A
DMS  A 903 (-3.5A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
PHE A 497
ASP A 442
SER A 438
TYR A 451
1.68A17.80
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
TYR E 508
VAL E 510
ILE E 410
ILE E 418
1.39A
DMS  E 902 (-4.0A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
VAL E 510
ILE E 410
ARG E 408
ILE E 418
1.54A
None
None
MLI  E 908 (-3.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
VAL A 510
ILE A 410
ARG A 408
ILE A 418
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
VAL A 510
ILE A 410
ARG A 408
ILE A 418
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
VAL E 510
ILE E 410
ARG E 408
ILE E 418
1.51A
None
None
MLI  E 908 (-3.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
TYR A 451
PHE A 497
ASP A 442
SER A 438
1.68A17.80
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
TYR E 451
PHE E 497
ASP E 442
SER E 438
1.72A17.80
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
PHE E 497
ASP E 442
SER E 438
TYR E 451
1.72A17.80
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
TYR A 508
VAL A 510
ILE A 410
ILE A 418
1.39A
DMS  A 903 (-3.5A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
TYR E 451
PHE E 347
SER E 438
ARG E 509
1.57A17.80
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
TYR E 451
PHE E 497
ASP E 442
SER E 438
1.78A17.80
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
VAL E 510
ILE E 410
ARG E 408
ILE E 418
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
TYR E 508
VAL E 510
ILE E 410
ILE E 418
1.40A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
PHE E 347
ARG E 346
ASP E 442
SER E 438
1.58A17.80
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
VAL E 510
ILE E 410
ARG E 408
ILE E 418
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
VAL E 350
ILE E 402
ILE E 410
ALA E 419
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
VAL E 350
ILE E 402
ILE E 410
ALA E 419
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
TYR E 508
VAL E 510
ILE E 410
ILE E 418
1.40A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
PHE E 347
SER E 438
ARG E 509
TYR E 451
1.59A17.80
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
PHE E 497
ASP E 442
SER E 438
TYR E 451
1.78A17.80
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
TYR A 209
VAL A 204
ILE A 281
ALA A 211
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
TYR A 209
VAL A 204
ILE A 281
ALA A 211
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
TYR A 508
VAL A 510
ILE A 410
ILE A 418
1.40A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
TYR A 508
VAL A 510
ILE A 410
ILE A 418
1.39A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
TYR A 451
PHE A 497
ASP A 442
SER A 438
1.72A18.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
PHE E 497
ASP E 442
SER E 438
TYR E 451
1.72A18.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
VAL A 510
ILE A 410
ARG A 408
ILE A 418
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
TYR E 508
VAL E 510
ILE E 410
ILE E 418
1.38A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
VAL E 510
ILE E 410
ARG E 408
ILE E 418
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
TYR E 508
VAL E 510
ILE E 410
ILE E 418
1.39A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
PHE A 497
ASP A 442
SER A 438
TYR A 451
1.73A18.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
VAL E 510
ILE E 410
ARG E 408
ILE E 418
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
PHE E 347
ARG E 346
ASP E 442
SER E 438
1.57A18.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
VAL A 510
ILE A 410
ARG A 408
ILE A 418
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
TYR E 451
PHE E 497
ASP E 442
SER E 438
1.72A18.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
TYR A 209
VAL A 204
ILE A 281
ALA A 211
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
TYR A 209
ARG A 217
ILE A 281
ALA A 211
1.32A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
TYR A 209
ARG A 217
ILE A 281
ALA A 211
1.29A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
TYR A 209
VAL A 204
ILE A 281
ALA A 211
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
TYR D 152
VAL D  30
ILE D  23
ALA D 124
1.44A
None
None
EDO  D 208 (-4.0A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
HIS D  94
VAL D  35
ILE D  23
ALA D  50
1.71A
None
None
EDO  D 208 (-4.0A)
EDO  D 206 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
TYR C 152
VAL C  30
ILE C  23
ALA C 124
1.54A
EDO  C 203 (-4.8A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
TYR D 152
VAL D  30
ILE D  23
ALA D 124
1.45A
None
None
EDO  D 208 (-4.0A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
TYR E 152
VAL E  30
ILE E  23
ALA E 124
1.43A
None
None
EDO  E 205 (-4.2A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
TYR A 152
VAL A  30
ILE A  23
ALA A 124
1.45A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
PHE D 156
ASP D 157
SER C  84
ALA C  60
1.52A17.50
EDO  D 209 ( 3.6A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
TYR B 152
VAL B  30
ILE B  23
ALA B 124
1.46A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
TYR A 152
VAL A  30
ILE A  23
ALA A 124
1.44A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
TYR E 152
VAL E  30
ILE E  23
ALA E 124
1.44A
None
None
EDO  E 205 (-4.2A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
TYR C 152
VAL C  30
ILE C  23
ALA C 124
1.53A
EDO  C 203 (-4.8A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
TYR B 152
VAL B  30
ILE B  23
ALA B 124
1.45A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
PHE D 156
ASP D 157
SER C  84
ALA C  60
1.52A17.50
EDO  D 209 ( 3.6A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
TYR A 152
VAL A  30
ILE A  23
ALA A 124
1.48A
None
None
APR  A 201 (-3.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
TYR C 152
VAL C  30
ILE C  23
ALA C 124
1.53A
None
None
APR  C 201 (-3.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
TYR C 152
VAL C  30
ILE C  23
ALA C 124
1.52A
None
None
APR  C 201 (-3.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
PHE D 156
ASP D 157
SER C  84
ALA C  60
1.63A17.50
EDO  D 204 (-3.9A)
None
None
EDO  D 204 ( 4.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
TYR B 152
VAL B  30
ILE B  23
ALA B 124
1.45A
None
None
APR  B 201 (-4.1A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
TYR E 152
VAL E  30
ILE E  23
ALA E 124
1.43A
None
None
APR  E 201 (-4.1A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
TYR A 152
VAL A  30
ILE A  23
ALA A 124
1.47A
None
None
APR  A 201 (-3.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
TYR B 152
VAL B  30
ILE B  23
ALA B 124
1.44A
None
None
APR  B 201 (-4.1A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
PHE D 156
ASP D 157
SER C  84
ALA C  60
1.62A17.50
EDO  D 204 (-3.9A)
None
None
EDO  D 204 ( 4.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
TYR E 152
VAL E  30
ILE E  23
ALA E 124
1.45A
None
None
APR  E 201 (-4.1A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
TYR D 152
VAL D  30
ILE D  23
ALA D 124
1.50A
None
None
APR  D 201 (-3.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
TYR D 152
VAL D  30
ILE D  23
ALA D 124
1.51A
None
None
APR  D 201 (-3.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
TYR A 152
VAL A  30
ILE A  23
ALA A 124
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
TYR A 152
VAL A  30
ILE A  23
ALA A 124
1.46A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
TYR B 152
VAL B  30
ILE B  23
ALA B 124
1.45A
None
None
EDO  B 202 (-4.0A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
TYR B 152
VAL B  30
ILE B  23
ALA B 124
1.47A
None
None
EDO  B 202 (-4.0A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
TYR C 152
VAL C  30
ILE C  23
ALA C 124
1.51A
None
None
EDO  C 206 (-4.1A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
TYR C 152
VAL C  30
ILE C  23
ALA C 124
1.50A
None
None
EDO  C 206 (-4.1A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7bqy MAIN PROTEASE
(SARS-CoV-2)		4 / 7
TYR A 209
VAL A 204
ILE A 281
ALA A 211
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7bqy MAIN PROTEASE
(SARS-CoV-2)		4 / 7
TYR A 209
VAL A 204
ILE A 281
ALA A 211
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7btf NSP12
(SARS-CoV-2)		4 / 7
TYR A 728
HIS A 725
VAL A  42
ILE A 715
1.43A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7btf NSP8
(SARS-CoV-2)		4 / 7
VAL D 130
ILE D 120
ILE D 106
ALA D 150
1.45A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7btf NSP8
(SARS-CoV-2)		4 / 7
VAL D 130
ILE D 120
ILE D 106
ALA D 150
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7btf NSP12
(SARS-CoV-2)		4 / 7
VAL A 182
ILE A 244
ARG A 132
ALA A 130
1.32A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7btf NSP12
NSP8
(SARS-CoV-2)		4 / 7
TYR A 273
VAL A 330
ILE B 120
ILE B 106
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7btf NSP12
(SARS-CoV-2)		4 / 7
TYR A 237
VAL A 182
ARG A 132
ALA A 125
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7btf NSP12
(SARS-CoV-2)		4 / 7
TYR A 479
VAL A 693
ILE A 579
ILE A 589
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7btf NSP12
NSP8
(SARS-CoV-2)		4 / 7
TYR A 273
VAL A 330
ILE B 120
ILE B 106
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7btf NSP12
(SARS-CoV-2)		4 / 7
TYR A 237
VAL A 182
ARG A 132
ALA A 125
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7btf NSP12
(SARS-CoV-2)		4 / 7
TYR A 237
VAL A 182
ILE A 244
ARG A 132
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7btf NSP12
(SARS-CoV-2)		4 / 7
TYR A 479
VAL A 693
ILE A 579
ILE A 589
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7btf NSP12
(SARS-CoV-2)		4 / 7
TYR A 728
HIS A 725
VAL A  42
ILE A 715
1.45A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7btf NSP12
(SARS-CoV-2)		4 / 7
TYR A 237
VAL A 182
ILE A 244
ARG A 132
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7btf NSP12
(SARS-CoV-2)		4 / 7
VAL A 182
ILE A 244
ARG A 132
ALA A 130
1.30A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		4 / 7
TYR A 209
VAL A 204
ILE A 281
ALA A 211
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		4 / 7
TYR A 209
VAL A 204
ILE A 281
ALA A 211
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7bv1 NSP12
(SARS-CoV-2)		4 / 7
TYR A 237
VAL A 182
ARG A 132
ALA A 125
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7bv1 NSP12
NSP8
(SARS-CoV-2)		4 / 7
TYR A 273
VAL A 330
ILE B 120
ILE B 106
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7bv1 NSP12
(SARS-CoV-2)		4 / 7
TYR A 237
VAL A 182
ILE A 244
ARG A 132
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7bv1 NSP12
(SARS-CoV-2)		4 / 7
TYR A 479
VAL A 693
ILE A 579
ILE A 589
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7bv1 NSP12
(SARS-CoV-2)		4 / 7
VAL A  96
ARG A 197
ILE A 201
ALA A 199
1.38A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7bv1 NSP12
(SARS-CoV-2)		4 / 7
TYR A 831
VAL A 880
ILE A 837
ARG A 836
1.46A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7bv1 NSP12
NSP8
(SARS-CoV-2)		4 / 7
TYR A 273
VAL A 330
ILE B 107
ALA B 110
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7bv1 NSP12
(SARS-CoV-2)		4 / 7
TYR A 237
VAL A 182
ILE A 244
ARG A 132
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7bv1 NSP12
(SARS-CoV-2)		4 / 7
VAL A 182
ILE A 244
ARG A 132
ALA A 130
1.36A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7bv1 NSP12
(SARS-CoV-2)		4 / 7
VAL A 182
ILE A 244
ARG A 132
ALA A 130
1.33A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7bv1 NSP12
(SARS-CoV-2)		4 / 7
TYR A 479
VAL A 693
ILE A 579
ILE A 589
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7bv1 NSP12
(SARS-CoV-2)		4 / 7
VAL A  96
ARG A 197
ILE A 201
ALA A 199
1.39A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7bv1 NSP12
(SARS-CoV-2)		4 / 7
TYR A 877
VAL A 880
ILE A 837
ARG A 836
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7bv1 NSP12
(SARS-CoV-2)		4 / 7
TYR A 877
VAL A 880
ILE A 837
ARG A 836
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7bv1 NSP12
(SARS-CoV-2)		4 / 7
TYR A 831
VAL A 880
ILE A 837
ARG A 836
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7bv1 NSP12
(SARS-CoV-2)		4 / 7
TYR A 237
VAL A 182
ARG A 132
ALA A 125
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7bv1 NSP12
NSP8
(SARS-CoV-2)		4 / 7
TYR A 273
VAL A 330
ILE B 120
ILE B 106
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7bv1 NSP12
NSP8
(SARS-CoV-2)		4 / 7
TYR A 273
VAL A 330
ILE B 107
ALA B 110
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
TYR A 217
ASP A 211
ALA A  97
ARG A 118
1.51A20.68
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7bv2 NSP12
NSP8
(SARS-CoV-2)		4 / 7
TYR A 273
VAL A 330
ILE B 120
ILE B 106
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
TYR A 479
VAL A 693
ILE A 579
ILE A 589
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
VAL A 182
ILE A 244
ARG A 132
ALA A 130
1.25A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
ASP A 211
ALA A  97
ARG A 118
TYR A 217
1.52A20.68
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7bv2 NSP12
NSP8
(SARS-CoV-2)		4 / 7
TYR A 273
VAL A 330
ILE B 107
ALA B 110
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7bv2 NSP12
NSP8
(SARS-CoV-2)		4 / 7
TYR A 273
VAL A 330
ILE B 107
ALA B 110
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
TYR A 237
VAL A 182
ARG A 132
ALA A 125
1.39A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
TYR A 728
HIS A 725
VAL A  42
ILE A 715
1.35A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
TYR A 479
VAL A 693
ILE A 579
ILE A 589
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
TYR A 728
HIS A 725
VAL A  42
ILE A 715
1.33A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7bv2 NSP12
NSP8
(SARS-CoV-2)		4 / 7
TYR A 273
VAL A 330
ILE B 120
ILE B 106
1.65A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
TYR A 237
VAL A 182
ILE A 244
ARG A 132
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
TYR A 237
VAL A 182
ARG A 132
ALA A 125
1.42A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
VAL A 182
ILE A 244
ARG A 132
ALA A 130
1.23A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_A_20JA602_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
TYR A 237
VAL A 182
ILE A 244
ARG A 132
1.56A
None